<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Oncology Institute Inc — News on 6ix</title>
<link>https://6ix.com/company/oncology-institute-inc</link>
<description>Latest news and press releases for Oncology Institute Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Mon, 27 Apr 2026 13:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/oncology-institute-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835cbe478dffbe2df11d597.webp</url>
<title>Oncology Institute Inc</title>
<link>https://6ix.com/company/oncology-institute-inc</link>
</image>
<item>
<title>The Oncology Institute Announces First Quarter 2026 Earnings Release Date and Conference Call</title>
<link>https://6ix.com/company/oncology-institute-inc/news/the-oncology-institute-announces-first-quarter-2026-earnings-release-date-and-conference-call</link>
<guid isPermaLink="true">https://6ix.com/company/oncology-institute-inc/news/the-oncology-institute-announces-first-quarter-2026-earnings-release-date-and-conference-call</guid>
<pubDate>Mon, 27 Apr 2026 13:00:00 GMT</pubDate>
<description>CERRITOS, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (“TOI”) (NASDAQ: TOI) a pioneer in value-based community oncology care, today announced that the company will release its first quarter 2026 financial results on Thursday, May 7, 2026, to be followed by a conference call the same day at 5:30 p.m. (Eastern Time). The conference call can be accessed live over the phone by dialing 1-800-225-9448 or for international callers, 1-203-518-9708. A replay will be available</description>
</item>
<item>
<title>The Oncology Institute Achieves $1.8 Million in Medicare Savings in CMS Enhancing Oncology Model Performance Period 3, Marking Significant Period-Over-Period Improvement</title>
<link>https://6ix.com/company/oncology-institute-inc/news/the-oncology-institute-achieves-dollar18-million-in-medicare-savings-in-cms-enhancing-oncology-model-performance-period-3-marking-significant-period-over-period-improvement</link>
<guid isPermaLink="true">https://6ix.com/company/oncology-institute-inc/news/the-oncology-institute-achieves-dollar18-million-in-medicare-savings-in-cms-enhancing-oncology-model-performance-period-3-marking-significant-period-over-period-improvement</guid>
<pubDate>Mon, 13 Apr 2026 04:00:00 GMT</pubDate>
<description>Practice earns maximum quality scores on avoidable ED visits and admissions for second consecutive period; per-episode savings exceed $6,400 CERRITOS, Calif.,</description>
</item>
<item>
<title>The Oncology Institute to Participate in the 25th Annual Needham Healthcare Conference</title>
<link>https://6ix.com/company/oncology-institute-inc/news/the-oncology-institute-to-participate-in-the-25th-annual-needham-healthcare-conference</link>
<guid isPermaLink="true">https://6ix.com/company/oncology-institute-inc/news/the-oncology-institute-to-participate-in-the-25th-annual-needham-healthcare-conference</guid>
<pubDate>Thu, 09 Apr 2026 13:00:00 GMT</pubDate>
<description>CERRITOS, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI), one of the largest value-based oncology groups in the United States, today announced that Dr. Daniel Virnich, Chief Executive Officer, and Rob Carter, Chief Financial Officer, will participate in the 25th Annual Needham Healthcare Conference, being held virtually on Wednesday, April 15, 2026, including a fireside chat at 3:45 p.m. ET. A webcast link of the presentation will be accessible through the</description>
</item>
<item>
<title>The Oncology Institute Names Minh Merchant Chief Legal Officer</title>
<link>https://6ix.com/company/oncology-institute-inc/news/the-oncology-institute-names-minh-merchant-chief-legal-officer</link>
<guid isPermaLink="true">https://6ix.com/company/oncology-institute-inc/news/the-oncology-institute-names-minh-merchant-chief-legal-officer</guid>
<pubDate>Mon, 06 Apr 2026 04:00:00 GMT</pubDate>
<description>CERRITOS, Calif., April 06, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (“TOI”) (NASDAQ: TOI), one of the largest value-based oncology groups in the</description>
</item>
<item>
<title>The Oncology Institute Reports Fourth Quarter and Full Year 2025 Financial Results and Guidance for 2026</title>
<link>https://6ix.com/company/oncology-institute-inc/news/the-oncology-institute-reports-fourth-quarter-and-full-year-2025-financial-results-and-guidance-for-2026</link>
<guid isPermaLink="true">https://6ix.com/company/oncology-institute-inc/news/the-oncology-institute-reports-fourth-quarter-and-full-year-2025-financial-results-and-guidance-for-2026</guid>
<pubDate>Thu, 12 Mar 2026 20:05:00 GMT</pubDate>
<description>CERRITOS, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI) (“TOI” or the “Company”), one of the largest value-based community oncology groups in the United States, today reported financial results for its fourth quarter and year ended December 31, 2025. Recent Operational Highlights Cash flow from operations in Q4 2025 was approximately $3.2 million, due to disciplined working capital management and overall increase in gross profit marginContinued expansion o</description>
</item>
<item>
<title>Tempus Announces Study Highlighting the Role of Advanced Genomic Profiling Features in Identifying Clinically Actionable Findings</title>
<link>https://6ix.com/company/oncology-institute-inc/news/tempus-announces-study-highlighting-the-role-of-advanced-genomic-profiling-features-in-identifying-clinically-actionable-findings-1</link>
<guid isPermaLink="true">https://6ix.com/company/oncology-institute-inc/news/tempus-announces-study-highlighting-the-role-of-advanced-genomic-profiling-features-in-identifying-clinically-actionable-findings-1</guid>
<pubDate>Wed, 11 Mar 2026 12:30:00 GMT</pubDate>
<description>CHICAGO, March 11, 2026--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the publication of a new study in JCO Precision Oncology highlighting how advanced features of comprehensive genomic profiling (CGP) expand treatment options for cancer patients in community oncology settings. The study, conducted in collaboration with The Oncology Institute (TOI), reveals that features such as tumor-normal matched sequencing, RNA</description>
</item>
<item>
<title>The Oncology Institute Announces Fourth Quarter and Full Year 2025 Earnings Release Date and Conference Call</title>
<link>https://6ix.com/company/oncology-institute-inc/news/the-oncology-institute-announces-fourth-quarter-and-full-year-2025-earnings-release-date-and-conference-call</link>
<guid isPermaLink="true">https://6ix.com/company/oncology-institute-inc/news/the-oncology-institute-announces-fourth-quarter-and-full-year-2025-earnings-release-date-and-conference-call</guid>
<pubDate>Thu, 26 Feb 2026 05:00:00 GMT</pubDate>
<description>CERRITOS, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (“TOI”) (NASDAQ: TOI) a pioneer in value-based community oncology care, today</description>
</item>
<item>
<title>The Oncology Institute to Participate in Multiple Healthcare Investor Conferences in March</title>
<link>https://6ix.com/company/oncology-institute-inc/news/the-oncology-institute-to-participate-in-multiple-healthcare-investor-conferences-in-march</link>
<guid isPermaLink="true">https://6ix.com/company/oncology-institute-inc/news/the-oncology-institute-to-participate-in-multiple-healthcare-investor-conferences-in-march</guid>
<pubDate>Wed, 25 Feb 2026 05:00:00 GMT</pubDate>
<description>CERRITOS, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI), a pioneer in value-based community oncology care, today</description>
</item>
<item>
<title>The Oncology Institute Appoints Kim Tzoumakas to Board of Directors</title>
<link>https://6ix.com/company/oncology-institute-inc/news/the-oncology-institute-appoints-kim-tzoumakas-to-board-of-directors</link>
<guid isPermaLink="true">https://6ix.com/company/oncology-institute-inc/news/the-oncology-institute-appoints-kim-tzoumakas-to-board-of-directors</guid>
<pubDate>Mon, 23 Feb 2026 05:00:00 GMT</pubDate>
<description>CERRITOS, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (“TOI”) (NASDAQ: TOI), one of the largest value-based oncology groups in the</description>
</item>
<item>
<title>The Oncology Institute Reaffirms 2025 Guidance and Provides Preliminary 2026 Outlook</title>
<link>https://6ix.com/company/oncology-institute-inc/news/oncology-institute-reaffirms-2025-guidance-130000538</link>
<guid isPermaLink="true">https://6ix.com/company/oncology-institute-inc/news/oncology-institute-reaffirms-2025-guidance-130000538</guid>
<pubDate>Mon, 12 Jan 2026 13:00:00 GMT</pubDate>
<description>CERRITOS, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI) (“TOI” or the “Company”), one of the largest value-based oncology groups in the United States, today reaffirmed 2025 guidance and provided its preliminary 2026 outlook. 2026 Outlook For 2026, TOI anticipates that total revenue will be in the range of $630 million to $650 million, reflecting 28% growth from the midpoint of 2025 and 2026 guidance ranges, and including approximately $150 million of Capita</description>
</item>
<item>
<title>The Oncology Institute Announces Leadership Promotions</title>
<link>https://6ix.com/company/oncology-institute-inc/news/oncology-institute-announces-leadership-promotions-130000597</link>
<guid isPermaLink="true">https://6ix.com/company/oncology-institute-inc/news/oncology-institute-announces-leadership-promotions-130000597</guid>
<pubDate>Fri, 09 Jan 2026 13:00:00 GMT</pubDate>
<description>Rakesh Panda appointed Chief Information Officer Nolan Mariano appointed Chief People Officer CERRITOS, Calif., Jan. 09, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI) announced today the promotions of Rakesh Panda to Chief Information Officer and Nolan Mariano to Chief People Officer. These promotions reinforce TOI’s continued focus on leading the way in value-based cancer care through further development of our technology-enabled care delivery platform as well as strengthe</description>
</item>
<item>
<title>The Oncology Institute Announces Addition of Board Member Mark Stolper</title>
<link>https://6ix.com/company/oncology-institute-inc/news/oncology-institute-announces-addition-board-133000446</link>
<guid isPermaLink="true">https://6ix.com/company/oncology-institute-inc/news/oncology-institute-announces-addition-board-133000446</guid>
<pubDate>Mon, 05 Jan 2026 13:30:00 GMT</pubDate>
<description>CERRITOS, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (“TOI”) (NASDAQ: TOI), one of the largest value-based oncology groups in the United States, today announced that Mark Stolper has joined the Board of Directors, effective January 2, 2026. Mr. Stolper brings significant public markets, financial and operational leadership experience to The Oncology Institute’s board. Mr. Stolper serves as Executive Vice President and Chief Financial Officer of RadNet, Inc. (NASDAQ: R</description>
</item>
<item>
<title>The Oncology Institute Announces Resignation of Board Member Gabe Ling</title>
<link>https://6ix.com/company/oncology-institute-inc/news/oncology-institute-announces-resignation-board-133000253</link>
<guid isPermaLink="true">https://6ix.com/company/oncology-institute-inc/news/oncology-institute-announces-resignation-board-133000253</guid>
<pubDate>Mon, 01 Dec 2025 13:30:00 GMT</pubDate>
<description>CERRITOS, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (“TOI”) (NASDAQ: TOI), one of the largest value-based oncology groups in the United States, today announced that Gabe Ling has resigned from the Board of Directors, effective December 1, 2025. A formal search process has been initiated to add new independent directors with complementary healthcare, clinical, and value-based care expertise. “On behalf of the Board of Directors, I want to thank Gabe for his service du</description>
</item>
<item>
<title>The Oncology Institute Reports Third Quarter 2025 Financial Results and Increases Full Year 2025 Guidance</title>
<link>https://6ix.com/company/oncology-institute-inc/news/oncology-institute-reports-third-quarter-210500391</link>
<guid isPermaLink="true">https://6ix.com/company/oncology-institute-inc/news/oncology-institute-reports-third-quarter-210500391</guid>
<pubDate>Thu, 13 Nov 2025 21:05:00 GMT</pubDate>
<description>CERRITOS, Calif., Nov. 13, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI) (“TOI” or the “Company”), one of the largest value-based community oncology groups in the United States, today reported financial results for its three months ended September 30, 2025 and updated its full year 2025 guidance. Recent Operational Highlights Fee-for-service revenue growth of 13% over Q3 2024, driven by continued organic growth performance in Florida and Oregon.Retail Pharmacy and Dispensar</description>
</item>
<item>
<title>Ascertain and The Oncology Institute Co-Develop ‘Touchless’ AI Automation for Oncology Administration</title>
<link>https://6ix.com/company/oncology-institute-inc/news/ascertain-and-the-oncology-institute-co-develop-touchless-ai-automation-for-oncology-administration</link>
<guid isPermaLink="true">https://6ix.com/company/oncology-institute-inc/news/ascertain-and-the-oncology-institute-co-develop-touchless-ai-automation-for-oncology-administration</guid>
<pubDate>Thu, 13 Nov 2025 21:04:00 GMT</pubDate>
<description>Partnership deployed touchless prior authorization system in eight weeks, achieving 95% reduction in authorization workloadCERRITOS, Calif. and NEW YORK, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Ascertain, a healthcare technology company pioneering agentic AI to automate administrative workflows, and The Oncology Institute, Inc. (NASDAQ: TOI), a leading value-based oncology care provider, today announced a co-development partnership to create “near-touchless” administrative workflows that reduce manual</description>
</item>
<item>
<title>The Oncology Institute Announces Third Quarter 2025 Earnings Release Date and Conference Call</title>
<link>https://6ix.com/company/oncology-institute-inc/news/oncology-institute-announces-third-quarter-204700903</link>
<guid isPermaLink="true">https://6ix.com/company/oncology-institute-inc/news/oncology-institute-announces-third-quarter-204700903</guid>
<pubDate>Wed, 22 Oct 2025 20:47:00 GMT</pubDate>
<description>CERRITOS, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (“TOI”) (NASDAQ: TOI), a pioneer in value-based community oncology care, today announced that the company will release its third quarter 2025 financial results after the market close on Thursday, November 13, 2025, to be followed by a conference call the same day at 5:00 p.m. (Eastern Time). The conference call can be accessed live over the phone by dialing 1-877-407-0789 or for international callers, 1-201-689-8562</description>
</item>
<item>
<title>The Oncology Institute to Participate in the Noble Capital Markets Emerging Growth Virtual Equity Conference</title>
<link>https://6ix.com/company/oncology-institute-inc/news/oncology-institute-participate-noble-capital-120000210</link>
<guid isPermaLink="true">https://6ix.com/company/oncology-institute-inc/news/oncology-institute-participate-noble-capital-120000210</guid>
<pubDate>Wed, 01 Oct 2025 12:00:00 GMT</pubDate>
<description>CERRITOS, Calif., Oct. 01, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute (NASDAQ: TOI), a pioneer in value-based community oncology care, today announced that Dr. Daniel Virnich, Chief Executive Officer, and Rob Carter, Chief Financial Officer, will participate in the Noble Capital Markets Emerging Growth Virtual Equity Conference, on October 8, 2025, including a presentation at 11:00am ET. Interested parties can access a webcast of the presentation by registering at the link listed on the Inv</description>
</item>
<item>
<title>The Oncology Institute Partners with Protocol Behavioral Health to Integrate Mental Health Services into Cancer Care</title>
<link>https://6ix.com/company/oncology-institute-inc/news/oncology-institute-partners-protocol-behavioral-120000240</link>
<guid isPermaLink="true">https://6ix.com/company/oncology-institute-inc/news/oncology-institute-partners-protocol-behavioral-120000240</guid>
<pubDate>Mon, 29 Sep 2025 12:00:00 GMT</pubDate>
<description>CERRITOS, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute (NASDAQ: TOI), a pioneer in value-based community oncology care, is pleased to announce a new partnership with Protocol Behavioral Health, a leading provider of evidence-based mental health care for cancer patients. This collaboration underscores TOI’s commitment to delivering whole-person care by integrating behavioral health services directly into the cancer care journey. Research shows that approximately 30% of cancer</description>
</item>
<item>
<title>The Oncology Institute Achieves $1.1 Million in Medicare Savings in CMS Enhancing Oncology Model Performance Period 2 through its California Professional Corporation</title>
<link>https://6ix.com/company/oncology-institute-inc/news/oncology-institute-achieves-1-1-120000639</link>
<guid isPermaLink="true">https://6ix.com/company/oncology-institute-inc/news/oncology-institute-achieves-1-1-120000639</guid>
<pubDate>Mon, 22 Sep 2025 12:00:00 GMT</pubDate>
<description>Practice earns maximum quality points on avoidable ED visits and admissions, saving more than $3,500 per episodeCERRITOS, Calif., Sept. 22, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute of Hope and Innovation (NASDAQ: TOI), a leading value-based oncology practice, achieved $1.1 million in Medicare savings during Performance Period 2 of the Centers for Medicare & Medicaid Services’ Enhancing Oncology Model (EOM) through its California professional corporation, with savings equating to more than</description>
</item>
<item>
<title>The Oncology Institute Launches Lung Cancer Center of Excellence in Florida Led by International Oncology Expert Dr. Edgardo Santos</title>
<link>https://6ix.com/company/oncology-institute-inc/news/oncology-institute-launches-lung-cancer-200500450</link>
<guid isPermaLink="true">https://6ix.com/company/oncology-institute-inc/news/oncology-institute-launches-lung-cancer-200500450</guid>
<pubDate>Tue, 02 Sep 2025 20:05:00 GMT</pubDate>
<description>CERRITOS, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute of Hope and Innovation (NASDAQ: TOI), a leading value-based oncology practice, today announced the launch of its Lung Cancer Center of Excellence in Fort Lauderdale, Florida. The new center will be led by world-renowned thoracic oncologist Dr. Edgardo S. Santos Castillero, whose career has been defined by groundbreaking research, clinical excellence, and a deep commitment to patient care. The Lung Cancer Center of Excell</description>
</item>
</channel>
</rss>